Merck (MRK)
130.42
-0.50 (0.38%)
Upcoming Events
Latest Headlines
Form 144 Merck & Co., Inc. Filed by: DeLuca Richard R.
August 11, 2026 4:15 PM - SEC Filing
Form 144 Merck & Co., Inc. Filed by: DeLuca Richard R.
August 11, 2026 10:27 AM - SEC Filing
Merck (MRK) PT Raised to $145 at Argus
August 11, 2026 7:12 AM - StreetInsider
Form 144 Merck & Co., Inc. Filed by: DeLuca Richard R.
August 10, 2026 4:43 PM - SEC Filing
Form 4 Merck & Co., Inc. For: Aug 06 Filed by: DeLuca Richard R.
August 10, 2026 4:28 PM - SEC Filing
Form 4 Merck & Co., Inc. For: Aug 05 Filed by: Maraldo David R.
August 7, 2026 4:22 PM - SEC Filing
Form 4 Merck & Co., Inc. For: Aug 05 Filed by: Williams David Michael
August 7, 2026 4:21 PM - SEC Filing
Form 4 Merck & Co., Inc. For: Aug 06 Filed by: Guindo Chirfi
August 7, 2026 4:19 PM - SEC Filing
Form 10-Q Merck & Co., Inc. For: Jun 30
August 7, 2026 4:13 PM - SEC Filing
Form 13F-HR Merck & Co., Inc. For: Jun 30
August 7, 2026 4:05 PM - SEC Filing
Form 144 Merck & Co., Inc. Filed by: Guindo Chirfi
August 6, 2026 4:47 PM - SEC Filing
Form 144 Merck & Co., Inc. Filed by: DeLuca Richard R.
August 6, 2026 4:45 PM - SEC Filing
Trump Administration Weighs Order On Autism And Vaccines - Bloomberg
August 6, 2026 4:36 PM - StreetInsider
FDA accepts Merck's sBLA for Enflonsia to cover second RSV season
August 6, 2026 6:45 AM - StreetInsider
U.S. FDA Accepts sBLA for ENFLONSIA™ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Ri
August 6, 2026 6:45 AM - BizWire
Form 144 Merck & Co., Inc. Filed by: Williams David Michael
August 5, 2026 4:29 PM - SEC Filing
Form 144 Merck & Co., Inc. Filed by: Maraldo David R.
August 5, 2026 4:29 PM - SEC Filing
Form 8-K Merck & Co., Inc. For: Aug 04
August 4, 2026 6:48 AM - SEC Filing
Merck shares rise on big Q2 earnings beat, adjusted FY outlook
August 4, 2026 6:47 AM - StreetInsider
Merck (MRK) Tops Q2 EPS by 14c, Beats on Revenue; Offers FY26 EPS Guidance
August 4, 2026 6:33 AM - StreetInsider
Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline
August 4, 2026 6:30 AM - BizWire
Merck (MRK) call put ratio 1.2 calls to 1 put into quarter results
August 3, 2026 10:33 AM - StreetInsider
Merck (MRK) call put ratio 1.3 calls to 1 put into quarter results
August 3, 2026 6:05 AM - StreetInsider
U.S. biopharma earnings: Eli Lilly (LLY), Pfizer (PFE) take the stage
August 1, 2026 10:00 AM - StreetInsider
Merck (MRK) call put ratio 2 calls to 1 put into quarter results
July 31, 2026 11:02 AM - StreetInsider
Merck (MRK) Declares $0.85 Quarterly Dividend; 2.6% Yield
July 29, 2026 11:04 AM - StreetInsider
Merck Announces Fourth-Quarter 2026 Dividend
July 29, 2026 11:04 AM - BizWire
Merck (MRK) PT Raised to $150 at Barclays
July 29, 2026 5:20 AM - StreetInsider
Merck (MRK) PT Raised to $105 at Bernstein SocGen Group
July 27, 2026 9:29 AM - StreetInsider
Merck signs HIV prevention drug licenses covering 129 countries
July 24, 2026 6:45 AM - StreetInsider
Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development
July 24, 2026 6:45 AM - BizWire
Tessera Therapeutics names former Merck executive as new CEO
July 23, 2026 1:00 PM - StreetInsider
Tessera Therapeutics Appoints Joseph Romanelli as President and Chief Executive Officer
July 23, 2026 1:00 PM - PR NewsWire
Gilead to present lenacapavir HIV trial data at AIDS 2026
July 21, 2026 10:00 AM - StreetInsider
Gilead and Merck HIV pill shows strong results in Phase 3 trials
July 21, 2026 10:00 AM - StreetInsider
Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure
July 21, 2026 10:00 AM - BizWire
Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy
July 21, 2026 10:00 AM - BizWire
Phanes expands Merck collaboration to study cancer drug combination
July 21, 2026 6:13 AM - StreetInsider
Guggenheim Reiterates Buy Rating on Merck (MRK)
July 17, 2026 7:07 AM - StreetInsider
Personalis (PSNL) explores potential sale after interest from Merck and others - source
July 16, 2026 3:28 PM - StreetInsider
MilliporeSigma Announces Opening of BioReliance® Testing Facility in Darmstadt, Germany to Support Drug Product Release in Europe
July 16, 2026 8:11 AM - Globe NewsWire
FDA approves Merck's Lipfendra as first oral PCSK9 inhibitor
July 16, 2026 6:45 AM - StreetInsider
Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia
July 16, 2026 6:45 AM - BizWire
Guggenheim Reiterates Buy Rating on Merck (MRK)
July 16, 2026 6:39 AM - StreetInsider
Merck to present HIV pipeline data at AIDS 2026 conference
July 15, 2026 7:00 AM - StreetInsider
Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026
July 15, 2026 7:00 AM - BizWire
Merck's Keytruda meets PFS endpoint in endometrial cancer trial
July 15, 2026 6:45 AM - StreetInsider
KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR)
July 15, 2026 6:45 AM - BizWire
Merck (MRK) PT Raised to $140 at JPMorgan
July 13, 2026 8:47 AM - StreetInsider
Merck (MRK) PT Raised to $142 at BMO Capital
July 13, 2026 7:34 AM - StreetInsider
Merck (MRK) PT Raised to $145 at Guggenheim
July 13, 2026 6:51 AM - StreetInsider
FDA clears Merck's Keytruda combo for muscle-invasive bladder cancer
July 10, 2026 2:10 PM - StreetInsider
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Ad
July 10, 2026 2:10 PM - BizWire
FDA grants breakthrough designation to EMD Serono's lupus drug enpatoran
July 8, 2026 8:00 AM - StreetInsider
EMD Serono Announces FDA Breakthrough Therapy Designation for Enpatoran in Lupus Patients with Active Skin Manifestations
July 8, 2026 8:00 AM - BizWire
Merck (MRK) PT Raised to $150 at Wells Fargo
July 8, 2026 6:29 AM - StreetInsider
Merck (MRK) PT Raised to $113 at Morgan Stanley
July 8, 2026 6:08 AM - StreetInsider
Merck (MRK) PT Raised to $150 at HSBC
July 6, 2026 1:35 AM - StreetInsider
Form 4 Merck & Co., Inc. For: Jun 30 Filed by: Seidman Christine E
July 1, 2026 8:47 AM - SEC Filing
Form 4 Merck & Co., Inc. For: Jun 30 Filed by: Karsanbhai Surendralal Lanca
July 1, 2026 8:45 AM - SEC Filing
Form 4 Merck & Co., Inc. For: Jun 30 Filed by: Coe Mary Ellen
July 1, 2026 8:42 AM - SEC Filing
Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4
July 1, 2026 6:45 AM - BizWire
Merck (MRK) PT Raised to $155 at Scotiabank
June 30, 2026 7:16 AM - StreetInsider
U.S. House committee opens investigation into Merck, AbbVie China drug trials - Reuters
June 30, 2026 6:02 AM - StreetInsider
Merck (MRK) PT Raised to $141 at BofA Securities
June 30, 2026 5:23 AM - StreetInsider
Merck reaches deal to expand HIV drug access via ADAP programs
June 29, 2026 6:45 AM - StreetInsider
Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV
June 29, 2026 6:45 AM - BizWire
FDA approves Merck's Keytruda combo with Trodelvy for TNBC
June 25, 2026 6:45 AM - StreetInsider
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS �
June 25, 2026 6:45 AM - BizWire
Form 11-K Merck & Co., Inc. For: Dec 31
June 24, 2026 3:12 PM - SEC Filing
Form 11-K Merck & Co., Inc. For: Dec 31
June 24, 2026 3:09 PM - SEC Filing
Form 11-K Merck & Co., Inc. For: Dec 31
June 24, 2026 3:05 PM - SEC Filing
The Quest to Repair What Multiple Sclerosis Takes Away
June 24, 2026 8:30 AM - StreetInsider
Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
June 24, 2026 8:30 AM - StreetInsider
EMD Serono names new global commercial head and North America president
June 24, 2026 8:15 AM - StreetInsider
EMD Serono Announces Healthcare Leadership Changes for Global Commercial Strategy and North America
June 24, 2026 8:15 AM - BizWire
EU approves Merck's Keytruda plus Padcev for bladder cancer
June 24, 2026 6:45 AM - StreetInsider
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resect
June 24, 2026 6:45 AM - BizWire
CICC Starts Merck (MRK) at Outperform
June 24, 2026 5:45 AM - StreetInsider
Merck KGaA, Darmstadt, Germany, Collaborates with Versant Ventures to Launch Saturnus Bio to Advance Treatments for Rare Genetic Cardiomyopathies
June 23, 2026 9:30 AM - BizWire
Merck's tulisokibart meets Phase 3 endpoints in ulcerative colitis trial
June 22, 2026 6:45 AM - StreetInsider
Merck’s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
June 22, 2026 6:45 AM - BizWire
FDA approves Merck's Capvaxive for children at higher pneumonia risk
June 18, 2026 6:45 AM - StreetInsider
U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease
June 18, 2026 6:45 AM - BizWire
Johnson & Johnson to stay out of obesity drugs, focus on cancer, CEO says
June 17, 2026 11:15 AM - StreetInsider
Study Reveals Dog Owners and Veterinarians See Challenges in Treating Allergic Skin Disease, Highlighting a Need for a Targeted Rapid Onset Treatment for Dogs of All Ages
June 17, 2026 6:45 AM - BizWire
German government to drop variable drug discounting plans - Reuters
June 15, 2026 6:08 AM - StreetInsider
FDA approves Merck's KEYTRUDA and WELIREG combination for kidney cancer
June 12, 2026 4:10 PM - StreetInsider
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG® (belzutifan), for Adjuvant Treatment of Certain Patients With Clear Ce
June 12, 2026 4:10 PM - BizWire
Merck Animal Health to acquire poultry technology firm TARGAN
June 11, 2026 6:45 AM - StreetInsider
Merck Animal Health to Acquire TARGAN
June 11, 2026 6:45 AM - BizWire
Gilead and Merck announce successful HIV treatment trial results
June 8, 2026 4:35 PM - StreetInsider
Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment
June 8, 2026 4:35 PM - BizWire
Merck and Gilead discontinue lung cancer drug combination trial
June 8, 2026 4:30 PM - StreetInsider
Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
June 8, 2026 4:30 PM - BizWire
MilliporeSigma Appoints New Heads of Discovery Solutions and Strategy & Business Development
June 8, 2026 8:00 AM - Globe NewsWire
Apotex launches sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, eligible for 180-day shared exclusivity
June 3, 2026 9:01 AM - PR NewsWire
Form 4 Merck & Co., Inc. For: May 29 Filed by: Warden Kathy J
June 2, 2026 4:15 PM - SEC Filing
Form 4 Merck & Co., Inc. For: May 29 Filed by: Karsanbhai Surendralal Lanca
June 2, 2026 3:32 PM - SEC Filing
Form 4 Merck & Co., Inc. For: May 29 Filed by: Coe Mary Ellen
June 2, 2026 2:27 PM - SEC Filing
Form 4 Merck & Co., Inc. For: May 29 Filed by: THULIN INGE G
June 2, 2026 2:21 PM - SEC Filing
Form 4 Merck & Co., Inc. For: May 29 Filed by: Seidman Christine E
June 2, 2026 2:20 PM - SEC Filing
Form 4 Merck & Co., Inc. For: May 29 Filed by: RUSSO PATRICIA F
June 2, 2026 2:18 PM - SEC Filing
Form 4 Merck & Co., Inc. For: May 29 Filed by: Rothman Paul
June 2, 2026 2:14 PM - SEC Filing
Form 4 Merck & Co., Inc. For: May 29 Filed by: Mayo Stephen
June 2, 2026 2:11 PM - SEC Filing
Form 4 Merck & Co., Inc. For: May 29 Filed by: LAVIZZO-MOUREY RISA J
June 2, 2026 2:10 PM - SEC Filing
Form 4 Merck & Co., Inc. For: May 29 Filed by: GLOCER THOMAS H
June 2, 2026 2:06 PM - SEC Filing
Form 4 Merck & Co., Inc. For: May 29 Filed by: Craig Pamela J.
June 2, 2026 2:03 PM - SEC Filing
Form 4 Merck & Co., Inc. For: May 29 Filed by: BAKER DOUGLAS M JR
June 2, 2026 1:57 PM - SEC Filing
Merck (MRK) Reiterated at Neutral by Cantor Fitzgerald
June 2, 2026 7:23 AM - StreetInsider
Guggenheim Reiterates Buy Rating on Merck (MRK)
June 2, 2026 6:48 AM - StreetInsider
Merck to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
June 2, 2026 6:45 AM - BizWire
Moderna and Merck report sustained melanoma treatment benefits at 5 years
June 1, 2026 8:01 AM - StreetInsider
Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASC
June 1, 2026 8:01 AM - StreetInsider
Form SD Merck & Co., Inc.
May 29, 2026 1:24 PM - SEC Filing
FDA grants breakthrough therapy designation to Merck's KRAS G12C inhibitor
May 29, 2026 6:49 AM - StreetInsider
FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung
May 29, 2026 6:45 AM - BizWire
Form 8-K Merck & Co., Inc. For: May 26
May 28, 2026 5:02 PM - SEC Filing
Merck to Participate in the Jefferies Global Healthcare Conference
May 28, 2026 6:45 AM - BizWire
Merck (MRK) Declares $0.85 Quarterly Dividend; 2.8% Yield
May 26, 2026 1:28 PM - StreetInsider
Merck Announces Third-Quarter 2026 Dividend
May 26, 2026 1:28 PM - BizWire
Form 8-K Merck & Co., Inc. For: May 22
May 22, 2026 4:21 PM - SEC Filing
China holds roundtable with over 50 foreign pharmaceutical firms
May 22, 2026 9:54 AM - StreetInsider
China Commerce Ministry holding meeting with foreign pharma companies including Lilly, Sanofi, Novartis, Merck
May 22, 2026 9:24 AM - StreetInsider
Merck receives EU committee approval recommendation for bladder cancer drug combo
May 22, 2026 7:55 AM - StreetInsider
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Cisplatin-Ineligible Resectable Muscle-Invasiv
May 22, 2026 7:55 AM - BizWire
Merck KGaA begins phase 3 trial for colorectal cancer drug
May 21, 2026 8:01 AM - StreetInsider
Merck KGaA, Darmstadt, Germany, Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer
May 21, 2026 8:00 AM - BizWire
Form 424B5 Merck & Co., Inc.
May 20, 2026 4:24 PM - SEC Filing
Synergis Software Launches Adept Cloud, a Cloud-Native Engineering Document Management Platform Built for Asset-Intensive Industries
May 20, 2026 11:02 AM - PR NewsWire
Form FWP Merck & Co., Inc. Filed by: Merck & Co., Inc.
May 19, 2026 6:02 AM - SEC Filing
Trump to unveil more discounted prescription drug options - CNBC
May 18, 2026 10:59 AM - StreetInsider
Form 424B5 Merck & Co., Inc.
May 18, 2026 8:14 AM - SEC Filing
Merck endometrial cancer drug meets survival goals in phase 3 trial
May 18, 2026 6:46 AM - StreetInsider
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or R
May 18, 2026 6:45 AM - BizWire
Form 13F-HR Merck & Co., Inc. For: Mar 31
May 13, 2026 4:07 PM - SEC Filing
Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities
May 13, 2026 8:33 AM - StreetInsider
Full Article List
